Email this article 
Albumin As a Resuscitative Fluid in Patients with Severe Sepsis: A Randomized Clinical Trial
Abstract
Fluid therapy is an essential part of resuscitation of the patients with severe sepsis and different methods has been suggested for. One of these methods is to add colloids like albumin to the crystalloid fluids, yet there are serious controversies about its effectiveness. To determine the effect of adding albumin to crystalloid fluids on the outcome of the severe sepsis, we performed this study. 20 patients (12 men and 8 women, with the mean age of 58) with severe sepsis who needed resuscitation, who were hospitalized in Imam Reza medical education center. The study began on march 2015 and ended on march 2016. The patients were randomized into two groups. One group received crystalloid fluids and routine management procedures and the other group received albumin (two vials of 20% albumin) alongside those two mentioned. Mortality was the primary endpoint. Secondary endpoints were the length of hospitalization, the need for mechanical ventilation, dialysis and organ failure. 28 and 90 day mortality in the albumin group was 10 and 40 percent, respectively (p value=0. 58), and they were 30 and 50 percent in the control group, respectively (p value=0. 5). None of the patients needed dialysis and there were no significant differences between the two groups from the organ failure point of view. The median length of hospitalization in both ICU and general ward was significantly higher in the albumin group (16 days VS 7.5 days, p value= 0.03 and 32 days VS 12 days, p value=0.02). PaO2 and O2Sat were lower but not significant in the albumin group. Adding albumin to the crystalloid fluids in order to resuscitate the patients with severe sepsis, only results in prolongation of the hospitalization length in both ICU and general ward and has no notable clinical benefit.
Trial registration www.IRCT.org/ IRCT 2016040316473N5
Keywords
Full Text:
PDFReferences
Quinlan GJ, Martin GS, Evans TW. (2005). Albumin: biochemical properties and therapeutic potential. Hepatology, 41 (6), 1211-1219.
Horsey PJ. (2002). The Cochrane 1998 Albumin Review--not all it was cracked up to be. Eur J Anaesthesiol, 19 (10), 701-704.
Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW.
(2004). Albumin influences total plasma antioxidant capacity favorably in
patients with acute lung injury. Crit Care Med, 32(3), 755-759.
Schwartz SI, Brunicardi FC (2010). Schwartz's principles of surgery, 9th ed. McGraw-Hill, Medical Pub. Division, New York, 1012-1015.
Leitch A, Craig G, Sadler P. (2013). Human Albumin Solution Resuscitation in Severe Sepsis and Septic Shock. Journal of the Intensive Care Society, 14(1), 45-52.
The SAFE Study Investigators Intensive Care Med (2011) 37: 86. doi:10.1007/s00134-010-2039-6
Delaney AP, Dan A, McCaffrey, J, Finfer S. (2011). The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and metaanalysis. Crit Care Med, 39(2), 386-391.
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. (2014). Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med, 370(15), 1412-1421.
Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. (2006). Sepsis in European intensive care units: results of the SOAP study. Crit Care Med, 34(2), 344-353.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. (2012). Drotrecogin alfa (activated) in adults with septic shock. N EnglJ Med, 366(22), 2055-2064.
Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. (2008). Vasopressin versus norepinephrine infusion in patients with septicshock. N Engl J Med, 358(9), 877-887.
Wilkes MM, Navickis RJ. (2001). Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med, 135(3), 149-164.
Patel A, Laffan MA, Waheed U, Brett SJ. (2014). Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ, 349g4561.
Chang R, Holcomb JB. (2016). Choice of Fluid Therapy in the Initial Management of Sepsis, Severe Sepsis, and Septic Shock. Shock.
Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, et al. (2006). Albumin administration improves organ function incritically ill hypoalbuminemic patients: A prospective, randomized,controlled, pilot study. Crit Care Med, 34(10), 2536-2540.
The SAFE Study Investigators (2006). Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ, 333(7577), 1044.
Goldwasser P, Feldman J. (1997). Association of serum albumin and mortality risk. J Clin Epidemiol, 50(6), 693-703.
Xu JY, Chen QH, Xie JF, Pan C, Liu SQ, Huang LW, et al. (2014). Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials. Crit Care, 18(6), 702.
Friedman G, Jankowski S, Shahla M, Gomez J, Vincent JL. (2008). Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients. J Clin Anesth, 20(7), 528-533.
Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, et al. (1983). Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med, 11(11), 839-850.
van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld AB. (2009). Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med, 37(4), 1275-1281.
Dolecek M, Svoboda P, Kantorova I, Scheer P, Sas I, Bibrova J, et al. (2009). Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. Hepatogastroenterology, 56(96), 1622-1628.
Trof RJ, Sukul SP, Twisk JW, Girbes AR, Groeneveld AB. (2010). Greater cardiac response of colloid than saline fluid loading in septic and non-septic critically ill patients with clinical hypovolaemia. Intensive Care Med, 36(4), 697-701.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. (2013). Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med, 41(2), 580-637.
Trof RJ, Sukul SP, Twisk JW, Girbes AR, Groeneveld AB. (2010). Greater cardiac response of colloid than saline fluid loading in septic and non-septic critically ill patients with clinical hypovolaemia. Intensive Care Med, 36(4),697-701.
Weil MH, Henning RJ, Puri VK. (1979). Colloid oncotic pressure: clinical significance. Crit Care Med, 7(3), 113-116.
Sudlow G, Birkett DJ, Wade DN. (1975). The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol, 11(6), 824-832.
Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge JM. (1998). Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin Sci (Lond), 95(4), 459-465.
Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. (1992). Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A, 89(16), 7674-7677.
Pro CI, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. (2014). A randomized trial of protocol-based care for early septic shock. N Engl J Med, 370(18), 1683-1693.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 345(19), 1368-1377.
Lilly CM. (2014). The ProCESS trial--a new era of sepsis management. N Engl J Med, 370(18), 1750-1751.
DOI: https://doi.org/10.7575/aiac.abcmed.17.05.04.02
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
2013-2023 (CC-BY) Australian International Academic Centre PTY.LTD.
Advances in Bioscience and Clinical Medicine